Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M. Source: BioSpace You Might Also Like This is How 47 Scientists Were Selected for the Chan-Zuckerberg Biohub February 12, 2017 <b>CapsoVision</b> Enhances CapsoCam Plus Capsule Endoscopy System With CapsoCloud September 7, 2017 Illumina Leaves Mission Bay for New Campus in the Peninsula February 15, 2018
